

Immunosuppressants (for SOT) Treatment Selector

Charts revised February 2019. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	ATV/c	ATV/r	DRV/c	DRV/r	LPV/r	DOR	EFV	ETV	NVP	RPV	MVC	BIC/ F/TAF	DTG	EVG/c/ F/TAF	EVG/c/ F/TDF	RAL	FTC or 3TC	F/TAF	TDF	ZDV
Corticosteroids																				
Prednisone	↑ ^a	↑ ^a	↑ ^a	↑ ^a	↑ ^a	↔	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Antimetabolites																				
Azathioprine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔ ^b
Mycophenolate	↔	↓	↔	↓	↓	↔	↓	↔	↓13%	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Calcineurin inhibitors																				
Ciclosporin	↑ ^e	↑ ^e	↑ ^e	↑ ^e	↑ ^e	↑	↓ ^e	↓ ^e	↓ ^e	↑	↑	↑ ^f	↔	↔	↔	↔	↔	↔	↔	↔
Tacrolimus	↑ ^e	↑ ^e	↑ ^e	↑ ^e	↑ ^e	↓ ^e	↓ ^e	↓ ^e	↓ ^e	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
mTOR inhibitors																				
Everolimus	↑ ^e	↑ ^e	↑ ^e	↑ ^e	↑ ^e	↔	↓ ^e	↓ ^e	↓ ^e	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Sirolimus	↑ ^e	↑ ^e	↑ ^e	↑ ^e	↑ ^e	↓ ^e	↓ ^e	↓ ^e	↓ ^e	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Other																				
Anti-thymocyte globulin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Basiliximab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Belatacept	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Colour Legend

	No clinically significant interaction expected.
	These drugs should not be coadministered.
	Potential interaction which may require a dose adjustment or close monitoring.
	Potential interaction predicted to be of weak intensity. No <i>a priori</i> dosage adjustment is recommended.

Text Legend

↑	Potential increased exposure of the immunosuppressant	↑	Potential increased exposure of HIV drug
↓	Potential decreased exposure of the immunosuppressant	↓	Potential decreased exposure of HIV drug
↔	No significant effect		

Numbers refer to increase or decrease in AUC as observed in drug-drug interaction studies.

Notes

- a Risk of elevated corticosteroid levels, Cushing's syndrome and adrenal suppression.
- b Potential additive haematotoxicity.
- c Concentrations of tenofovir-DF may increase, but no effect on elvitegravir, cobicistat or emtricitabine is expected. Monitor renal function.
- d Monitor renal function.
- e TDM of immunosuppressant is recommended.
- f Coadministration may increase concentrations of bicitegravir and tenofovir alafenamide; no effect on emtricitabine is expected.
- g Coadministration may increase concentrations of tenofovir alafenamide; no effect on emtricitabine is expected.